



**Commentary – *Pharmacopeial Forum* 38(3) [May–Jun. 2012]  
Interim Revision Announcements to *USP 36-NF 31***

In accordance with USP's Rules and Procedures of the Council of Experts, USP publishes all proposed revisions to the *United States Pharmacopeia and the National Formulary (USP-NF)* for public review and comment in the *Pharmacopeial Forum (PF)*, USP's bimonthly journal for public notice and comment. After comments are considered and incorporated as the Expert Committee deems appropriate, the proposal may advance to official status or be republished in *PF* for further notice and comment, in accordance with the Rules and Procedures. In cases when proposals advance to official status without republication in *PF*, a summary of comments received and the appropriate Expert Committee's responses are published in the *Revisions and Commentary* section of the USP Web site at the time the revision is published.

The *Commentary* is not part of the official text and is not intended to be enforceable by regulatory authorities. Rather, it explains the basis of Expert Committees' responses to public comments. If there is a difference between the contents of the *Commentary* and the official text, the official text prevails. In case of a dispute or question of interpretation, the language of the official text, alone and independent of the *Commentary*, shall prevail.

For further information, contact:  
USP Executive Secretariat  
United States Pharmacopeia  
12601 Twinbrook Parkway  
Rockville, MD 20852-1790

**Monograph/Section(s):** *Heparin Sodium Injection / Labeling*  
**Expert Committee:** Monographs–Biologics and Biotechnology 1  
**No. of Commenters:** 1

**Comment Summary #1:** The commenter suggested that the proposed language for the new requirement for labeling strength and total volume is unclear. The commenter recommends clarifying the labeling language and to include reference to <1> *Injection* in the Labeling section.

**Response:** Comment incorporated.